ClinicalTrials.gg
TerminatedNCT02743078Updated Jun 2, 2021Results posted

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

A Phase 2 interventional study of Bevacizumab and TTFields Therapy in Glioblastoma, Glioma and Gliosarcoma, sponsored by RTOG Foundation, Inc.. Terminated at 11 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by RTOG Foundation, Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Treatment now available commercially

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies testing bevacizumab in Glioblastoma — 8 open to participants now, 13 under way, 1 of them phase 3. Bevacizumab · Glioblastoma.

Enrollment
88th of 97
3 · median 48
Started
2017
with 2 others
Phase 2
57 of 97
3 open now
Registered
71st of 97
by date

Among the 97 studies testing bevacizumab in Glioblastoma, this one is the 88th largest by enrollment, is one of 3 that started in 2017, is one of 57 in phase 2, and was the 71st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 97 studies testing bevacizumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing bevacizumab in Glioblastoma, or all of them as a file.
02

Study summary

This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor Treating Fields [TTFields] Therapy) to bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma.

Read the detailed description

Patients that have recurrent glioblastoma that has progressed on bevacizumab continue to receive bevacizumab with the addition of Tumor Treating Fields Therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

03

Conditions studied

  • Glioblastoma
  • Glioma
  • Gliosarcoma

Keywords

  • Glioblastoma
  • Glioma
  • Gliosarcoma
  • Optune
  • TTFields
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven diagnosis of glioblastoma or other grade IV malignant glioma (including variants of glioblastoma i.e., gliosarcoma, giant cell glioblastoma, etc.).
  • Confirmation of tumor recurrence or progression on contrast magnetic resonance imaging (MRI) (with and without gadolinium contrast) as determined by Response assessment in neuro-oncology (RANO) criteria within 14 days prior to registration for patients who did not have recent resection of their glioblastoma or only had a stereotactic .
  • Patients having undergone recent resection (within 5 weeks prior to registration) of their glioblastoma to treat current recurrence prior to study treatment must have recovered from the effects of surgery (including patient's skin having fully recovered from the surgical wound) Note: a 4-week window is required after surgery prior to starting treatment. For central nervous system (CNS) -related stereotactic biopsies, a minimum of 7 days must have elapsed prior to registration.
  • Residual disease of recurrent glioblastoma is not mandated for eligibility into the study. To best assess the extent of residual disease post-operatively, a post-operative MRI scan must be performed prior to registration and is recommended to be within 96 hours post-surgery (although 24-48 hours would be optimum). Note: Patients who did have surgery with a post-operative contrast-enhanced scan falling outside the 5-week window prior to registration, must have a repeat MRI scan within 14 days prior to registration.
  • Patients with up to two recurrences are allowed.
  • Failure on bevacizumab (either as a monotherapy or a combination) as most recent regimen confirmed by tumor recurrence on MRI.

    • The patient must have failed no more than one regimen of bevacizumab.
    • The patient must not have received bevacizumab as an upfront treatment in newly diagnosed glioblastoma.
    • There must be a minimum of 14 days (i.e., an interval equal to or greater than 14 days) since last treatment with bevacizumab and registration
  • History/physical examination within 14 days prior to registration
  • performance status ≥ 70 within 14 days prior to registration
  • Age ≥ 22
  • (ANC) ≥ 1,000 cells/mm3
  • ≥ 75,000 cells/mm3
  • (Hgb) ≥ 9.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g/dl is acceptable.)
  • Creatinine ≤ 1.5 mg/dl
  • Urine protein: creatinine (UPC) ratio \< 1.0 within 14 days prior to registration OR urine dipstick for proteinuria ≤ 2+ (patients discovered to have > 2+ proteinuria on dipstick urinalysis at baseline must have a UPC ratio done that is \<1.0 to be eligible. If the UPC ratio is ≥ 1.0 then the patients should undergo a 24-hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).

    *Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm. UPC ratio is calculated using one of the following formulas:

    • [urine protein]/[urine creatinine]: if both protein and creatinine are reported in mg/dL
    • [(urine protein) x0.088]/[urine creatinine]: if urine creatinine is reported in mmol/L
  • Serum total ≤ 1.5 x (ULN) within 14 days prior to registration
  • (ALT) and aspartate transaminase (AST) ≤ 3.0 x ULN within 14 days prior to registration
  • Patients on full dose anticoagulants (e.g., warfarin or low molecular weight (LMW) heparin) must meet both of the following criteria:

    1. No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) within 14 days prior to registration
    2. One of the below criteria must be met based on patient's therapy:

      1. Warfarin: In-range (INR) (usually between 2 and 3) within 14 days prior to registration
      2. LMW heparin or novel oral anti-coagulant: stable dose within 14 days prior to registration
  • Patients must have recovered from the toxic effects of prior therapy at the time of registration as follows:

    • 28 days from the administration of any agent
    • 28 days from administration of prior cytotoxic therapy with the following exceptions:

      • 14 days from administration of vincristine or irinotecan
      • 42 days from administration of nitrosoureas
      • 21 days from administration of procarbazine
    • 7 days from administration of non-cytotoxic agents [e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count)]

      • Female patients of must have a negative serum pregnancy test within 14 days prior to registration.
      • Patient must be maintained on a stable or decreasing dose of for at least 5 days before the baseline scan.
      • Minimum interval since completion of radiation treatment at the time of registration is 90 days.
      • Patient must provide study specific prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Prior invasive (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years. (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
  • Infra-tentorial tumor.
  • > 1 cm diameter of blood seen on contrast MRI (with and without gadolinium contrast)
  • Major surgery such as intra-thoracic, intra-abdominal or intra-pelvic (with the exception of craniotomy), open or significant traumatic injury ≤ 4 weeks prior to registration, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device ≤ 1 week prior to registration, or who have not recovered from side effects of such procedure or injury.
  • Implanted pacemaker, defibrillator or deep brain stimulator, other implanted electronic devices in the brain.
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration.
  • Transmural myocardial infarction within the last 6 months prior to registration
  • Cerebrovascular accident (CVA), (TIA) within the last 6 months prior to registration
  • Pulmonary embolism (PE) within the last 6 months prior to registration
  • Uncontrolled hypertension (defined by a systolic blood pressure (SBP) ≥ 160 mm Hg or diastolic blood pressure (DBP) ≥ 100 mm Hg while on anti-hypertensive medications) within 14 days prior to registration.
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
  • Chronic lung disease or exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
  • Severe hepatic disease, defined as a diagnosis of Class B or C hepatic disease.
  • Known positive patients.
  • Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • Skull defects such as missing bone flap, a shunt, or bullet fragments.
  • Significant intracranial pressure as per treating physician that may require surgical intervention.
  • Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of .
  • Breast feeding women.
  • Prior allergic reaction to bevacizumab or severe adverse event with bevacizumab.
  • Known sensitivity to conductive hydrogels.
  • Prior treatment with the Optune® system.
  • Active treatment on another clinical trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Bevacizumab and TTFields Therapy

    Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.

    Drug: Bevacizumab · Device: TTFields Therapy

Interventions

  • 10 mg/kg every 2 weeks intravenously over 30 minutes.

    Also known as: Avastin

  • DeviceTTFields Therapy

    Device is worn continuously at least 18 hours a day on average, with 1-3 days off every four weeks.

    Also known as: Optune, Tumor Treating Fields Therapy, TTF Therapy

06

What researchers measure

Primary outcomes

  1. Overall Survival at 6 Months

    Number of participants alive at 6 months. Out of the planned 80 eligible patients, if 36 or more were alive at six months then the null hypothesis that the six-month survival rate is 35% or less would be rejected, concluding that the six-month survival is at least 35%. No testing was done due to the small number of participants resulting from early study closure.

    Time frame: From registration to six months

Secondary outcomes

  1. Overall Survival (OS)

    Survival time is defined as time from registration the to date of death from any cause or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive at time of study termination is reported.

    Time frame: From registration to study termination. Maximum follow-up was 21.8 months.

  2. Progression-Free Survival

    Progression is defined by the Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria. (The precise definition is too long to be included here.) Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up. Progression-free survival rates were to be estimated using the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without progression at time of study termination is reported.

    Time frame: From registration to study termination. Maximum follow-up was 21.8 months.

  3. Number of Participants With Partial or Complete Response

    Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria was used to define response and progression. (The precise definitions are too long to be included here.) Objective response is defined as complete or partial response. The percentage of participants with objective response was to be estimated using the exact binomial method with accompanying 95% confidence intervals. Given the small number of participants due to early study closure, only the number of patients with objective response is reported.

    Time frame: From registration to study termination. Maximum follow-up was 21.8 months.

  4. Number of Participants With Grade 3+ Treatment-related Adverse Events

    Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the adverse event (AE). The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. The percentage of participants with grade 3 or higher treatment-related adverse events was to be estimated using the exact binomial method with accompanying 95% confidence intervals.

    Time frame: From registration to study termination. Maximum follow-up was 21.8 months.

07

Results

Posted Nov 17, 2020
Limitations and caveats
This study stopped accrual early due to unmet targeted accrual goals with 3 subjects accrued out of 85 planned.

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab and TTFields Therapy
Started3
Eligible populaton3
Eligible with six-month follow-up data3
Completed3
Not completed0

Outcome measures

PrimaryOverall Survival at 6 Months

Number of participants alive at 6 months. Out of the planned 80 eligible patients, if 36 or more were alive at six months then the null hypothesis that the six-month survival rate is 35% or less would be rejected, concluding that the six-month survival is at least 35%. No testing was done due to the small number of participants resulting from early study closure.

Time frame:
From registration to six months
Reported as:
Count of participants · Participants
Overall Survival at 6 Months
ParticipantsBevacizumab and TTFields Therapy
Overall Survival at 6 Months1
SecondaryOverall Survival (OS)

Survival time is defined as time from registration the to date of death from any cause or last known follow-up (censored) and was to be estimated by the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive at time of study termination is reported.

Time frame:
From registration to study termination. Maximum follow-up was 21.8 months.
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsBevacizumab and TTFields Therapy
Overall Survival (OS)1
SecondaryProgression-Free Survival

Progression is defined by the Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria. (The precise definition is too long to be included here.) Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up. Progression-free survival rates were to be estimated using the Kaplan-Meier method. Given the small number of participants due to early study closure, only the number of patients last reported to be alive without progression at time of study termination is reported.

Time frame:
From registration to study termination. Maximum follow-up was 21.8 months.
Reported as:
Count of participants · Participants
Progression-Free Survival
ParticipantsBevacizumab and TTFields Therapy
Progression-Free Survival0
SecondaryNumber of Participants With Partial or Complete Response

Modified Response Assessment in Neuro-Oncology (RANO) Response Criteria was used to define response and progression. (The precise definitions are too long to be included here.) Objective response is defined as complete or partial response. The percentage of participants with objective response was to be estimated using the exact binomial method with accompanying 95% confidence intervals. Given the small number of participants due to early study closure, only the number of patients with objective response is reported.

Time frame:
From registration to study termination. Maximum follow-up was 21.8 months.
Reported as:
Count of participants · Participants
Number of Participants With Partial or Complete Response
ParticipantsBevacizumab and TTFields Therapy
Number of Participants With Partial or Complete Response0
SecondaryNumber of Participants With Grade 3+ Treatment-related Adverse Events

Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grade refers to the severity of the adverse event (AE). The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild, Grade 2 Moderate, Grade 3 Severe, Grade 4 Life-threatening or disabling, Grade 5 Death related to AE. The percentage of participants with grade 3 or higher treatment-related adverse events was to be estimated using the exact binomial method with accompanying 95% confidence intervals.

Time frame:
From registration to study termination. Maximum follow-up was 21.8 months.
Reported as:
Count of participants · Participants
Number of Participants With Grade 3+ Treatment-related Adverse Events
ParticipantsBevacizumab and TTFields Therapy
Number of Participants With Grade 3+ Treatment-related Adverse Events2

Adverse events

Collected over Every 28th day during treatment, at progression, then every 8 weeks for one year, then every 12 weeks for one year, then every 6 months. Maximum follow-up at time of study termination was 21.8 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab and TTFields Therapy2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventBevacizumab and TTFields Therapy
Intracranial hemorrhageNervous system disorders1/3
Reversible posterior leukoencephalopathy syndromeNervous system disorders1/3
Most frequent other events
Showing 10 of 11
Most frequent other events
EventBevacizumab and TTFields Therapy
Rash maculo-papularSkin and subcutaneous tissue disorders3/3
FatigueGeneral disorders1/3
PainGeneral disorders1/3
Urinary tract infectionInfections and infestations1/3
Alanine aminotransferase increasedInvestigations1/3
Alkaline phosphatase increasedInvestigations1/3
DysphasiaNervous system disorders1/3
HeadacheNervous system disorders1/3
Reversible posterior leukoencephalopathy syndromeNervous system disorders1/3
InsomniaPsychiatric disorders1/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bevacizumab and TTFields Therapy
Median55 (34 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab and TTFields Therapy
Female1
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bevacizumab and TTFields Therapy
Hispanic or Latino1
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bevacizumab and TTFields Therapy
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
08

Study locations

11 sites
  • University of California, San Diego
    La Jolla, California 92093, United States
  • University of California Irvine, Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • Miami Cancer Institute at Baptist Health
    Miami, Florida 33176, United States
  • UF Health Cancer Center at Orlando Health
    Orlando, Florida 32806, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63100, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Oct 2019, 29 months.

Results were first posted in Nov 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 19, 2016
StartActual
May 9, 2017
Primary completionActual
Oct 15, 2019
CompletionActual
Oct 15, 2019
Results first posted
Nov 17, 2020
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02743078
Lead sponsor
RTOG Foundation, Inc.
Collaborators
NovoCure Ltd.
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
May 9, 2017
Primary completion
Oct 15, 2019
Completion
Oct 15, 2019
Results posted
Nov 17, 2020
Last update
Jun 2, 2021

Study contacts

Manmeet Ahluwalia, MD, FACP
principal investigator · RTOG Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion